Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ

CompletedOBSERVATIONAL
Enrollment

700

Participants

Timeline

Start Date

April 25, 2016

Primary Completion Date

February 12, 2020

Study Completion Date

February 12, 2020

Conditions
Major Depressive Disorder
Trial Locations (22)

13496

Bundang Cha Medical Center, Seongnam-si

13618

Roa Neurology Clinic/Neurology, Bundang-gu, Seongnam-si

18450

Hallym University Dongtan Sacred Heart Hospital/Department of Neuropsychiatry, Hwaseong-si

24253

Chuncheon Sacred Heart Hospital-Hallym University, Gangwon-do

27376

Konkuk University Chungju Hospital / Department of Psychiatry, Chungju

61453

Chosun University Hospital, Gwangju

61469

Chonnam National University Hospital, Gwangju

362-711

Chungbuk National University Hospital, Cheongju-si

431-796

Hallym University Sacred Heart Hospital, Anyang-si

411-706

Inje University Ilsan Paik Hospital, Goyang-si

601-723

Bong Seng Memorial Hospital, Busan

602-739

Pusan National University Hospital, Busan

700-721

Kyungpook National University Hospital, Daegu

301-721

Chungnam National University Hospital, Daejeon

560-750

Presbyterian Medical Center, Jeonju

01830

Nowon Eulji Medical Center, Eulji University, Seoul

02841

Korea University Anam Hospital, Seoul

03080

Seoul National University Hospital, Seoul

04763

Hanyang University Seoul Hospital, Seoul

06973

Chung-Ang University Hospital, Seoul

143-729

Konkuk University Medical Center, Seoul

Unknown

Kyung Hee University Hospital at Gangdong Department of Psychiatry, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02548949 - Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ | Biotech Hunter | Biotech Hunter